Format

Send to

Choose Destination
Biomed Pharmacother. 2015 Dec;76:24-9. doi: 10.1016/j.biopha.2015.10.020. Epub 2015 Nov 9.

Multiple-purpose immunotherapy for cancer.

Author information

1
lmmanuel Kant Baltic Federal University, 3 Botkin str., 236016 Kaliningrad, Russia. Electronic address: seledtsov@rambler.ru.
2
lmmanuel Kant Baltic Federal University, 3 Botkin str., 236016 Kaliningrad, Russia.
3
Institute of Clinical Immunology, 14 Ydrintsevskaya str., 630099 Novosibirsk, Russia.

Abstract

Anti-cancer vaccination is a useful strategy to elicit antitumor immune responses, while overcoming immunosuppressive mechanisms. Whole tumor cells or lysates derived thereof hold more promise as cancer vaccines than individual tumor-associated antigens (TAAs), because vaccinal cells can elicit immune responses to multiple TAAs. Cancer cell-based vaccines can be autologous, allogeneic or xenogeneic. Clinical use of xenogeneic vaccines is advantageous in that they can be most effective in breaking the preexisting immune tolerance to TAAs. An attractive protocol would be to combine vaccinations with immunostimulating and/or immunosuppression-blocking modalities. It is reasonable to anticipate that combined immunotherapeutic strategies will allow for substantial improvements in clinical outcomes in the near future.

KEYWORDS:

Antitumor immunoprotection; Cancer cell-based vaccines; Combined immunotherapy; Immunosuppression

PMID:
26653546
DOI:
10.1016/j.biopha.2015.10.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center